Navigation Links
Testing Lung Cancer Patients for Gene May Aid Treatment, Study Finds
Date:4/22/2013

By Maureen Salamon
HealthDay Reporter

MONDAY, April 22 (HealthDay News) -- Lung cancer patients carrying a rare gene mutation may experience delayed disease progression with drugs often taken by those with breast cancer, a new study suggests.

European researchers found that patients with non-small cell lung cancer who took drugs targeting so-called HER2 proteins -- which result from gene mutations in less than 5 percent of lung cancers -- experienced an extra five months of progression-free survival.

"We were favorably surprised by the outcome of patients and the promising activity of drugs that are usually dedicated to breast cancer patients," said study author Dr. Julien Mazieres, a professor of pulmonology at Larrey Hospital in Toulouse, France. "We do think that all lung [cancers] should be tested for HER2 as is done in France."

The study was published April 22 in the Journal of Clinical Oncology.

Non-small cell is the most common type of lung cancer -- the type seen in about 85 percent of lung cancer cases, according to the American Cancer Society. More than 200,000 Americans are diagnosed with lung cancer each year and 158,000 die from it, according to the U.S. Centers for Disease Control and Prevention.

HER2-positive cancer tests positive for a protein called human epidermal growth factor receptor 2, which feeds the growth of cancer cells and is caused by a gene mutation.

Mazieres and his colleagues identified this mutation in 65 non-small cell lung cancer patients, administering anti-HER2 drugs such as Herceptin (trastuzumab), which also is used to target HER2 in breast cancer patients.

Half of the patients were already at stage 4 lung cancer when diagnosed, while others were at earlier stages of the disease. Notably, most participants with the gene mutation were women, more than half of whom had never smoked.

The extra five months of progression-free survival experienced by patients undergoing HER2 therapies "is a big deal in the cancer business," said Dr. Norman Edelman, chief medical officer of the American Lung Association.

"It's not absolutely a new finding, but it's another study in what is a very exciting field now in cancer," Edelman said. "Up until now, we've treated cancers ... using an elephant gun. This new field looks at the genetic makeup of individual tumors to see if we can attack them in a specific way, not a general way."

Although only a small percentage of lung cancer patients carry this gene mutation, Edelman recommended that all patients be tested for it.

"It's useful and it's being done," he said. "If I had somebody I cared about who I thought had lung cancer, I would say to only go to a center where they're doing this testing. The odds are strong they will not be benefited [by anti-HER2 drugs], but lung cancer is a devastating disease."

Mazieres and Edelman agreed that future research in this area should focus on large clinical trials, which are costly but can tease out various genetic abnormalities that are important to tumor growth.

More information

The U.S. National Library of Medicine has more about lung cancer.

SOURCES: Julien Mazieres, M.D., Ph.D., professor, pulmonology, Larrey Hospital, Toulouse, France; Norman Edelman, M.D., chief medical officer, American Lung Association; April 22, 2013, Journal of Clinical Oncology


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Austin Web Design Firm Fahrenheit Marketing to Launch Qwestrix Loyalty Program in Beta Testing
2. Improved molecular tools streamline influenza testing and management
3. Request A Test is Now Offering More Choices for Magnesium Testing
4. Personalizing prostate specific antigen testing may improve specificity, reduce biopsies
5. The Gluten Free Society Launches Gluten Sensitivity and Celiac Disease At-Home Testing
6. DISC Personality Testing in the Workplace by PeopleKeys: A New Strategy for Building Successful Teams
7. Oregon Canna-Businesses Take One Small Step For Dispensaries, One Giant Leap For Testing Labs
8. Advances in molecular testing offer new hope for lung cancer patients
9. HIV self-testing: The key to controlling the global epidemic
10. Could Self-Testing Help Overcome HIV/AIDS Epidemic?
11. Request A Test Offers 10% off STD testing in April 2013
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Testing Lung Cancer Patients for Gene May Aid Treatment, Study Finds
(Date:6/22/2017)... ... June 22, 2017 , ... Plastic Surgery Associates is ... Top Doctor for 2017. Each year, research and information firm, Castle Connolly, releases their ... title in 2015, this marks the 3rd time that Dr. Canales has ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... grant from the American Heart Association (AHA) to launch a Rheumatic Heart Disease ... the prevention and diagnosis of rheumatic heart disease (RHD) in high-risk, financially disadvantaged ...
(Date:6/22/2017)... ... June 22, 2017 , ... Vighter, a premier ... received certification for ANSI/ASIS PSC.1-2012. The company’s work in countries throughout Southwest Asia, ... of law has been degraded. The PSC.1 standard was created to protect fundamental ...
(Date:6/20/2017)... Tennessee (PRWEB) , ... June 20, 2017 , ... ... care services, announced today that Claritas Capital, a Nashville-based private equity firm, has ... accelerate our expansion plans for some time, and Claritas Capital offers the smart ...
(Date:6/20/2017)... ... 2017 , ... After months of negotiations, FaceCradle USA is proud to announce the debut of ... , “Introducing our product on QVC is something we all worked hard to achieve for ... more than 90 million homes in the United States,” said FaceCradle USA President Dylan Doherty. ...
Breaking Medicine News(10 mins):
(Date:6/10/2017)... BESSEMER, Ala. , June 9, 2017  Shane K. Burchfield, ... Member recognized for excellence as a Podiatrist in Alabama ... of Podiatry at Family First Foot Care. He brings over 20 ... sports medicine, pain management and healthcare, to his role. ... Family First Foot Care, PC is pleased to welcome ...
(Date:6/8/2017)... , June 8, 2017  StatLab ... leading developer and manufacturer of diagnostic supplies ... today that Cressey & Company LP ("Cressey ... has completed a growth-focused investment in the ... majority ownership position from selling shareholder, Prairie ...
(Date:6/5/2017)... , June 5, 2017 Kohll,s Pharmacy ... the United States . The Raizer is ... a fallen person up to an almost-standing position ... and operated by one assistant and does not ... is simple enough that a child can operate it, ...
Breaking Medicine Technology: